Welcome to our dedicated page for Niki BioSolutions SEC filings (Ticker: NIKI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Niki BioSolutions's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Niki BioSolutions's regulatory disclosures and financial reporting.
Niki BioSolutions, Inc. (NIKI) disclosed new executive arrangements following its previously announced merger. Ian Huen is serving as Chief Executive Officer under an appointment letter effective August 1, 2026, with an initial six‑month term and a monthly base salary of HKD 210,000 (approximately USD 26,800). He is eligible for discretionary cash bonuses, share bonuses and stock options under the company’s share option plan, and either party may terminate his appointment with one month’s notice, subject to specified events.
Alidad Mireskandari will serve as President and Chief Operating Officer under an employment agreement dated September 1, 2026, with an annual base salary of USD 320,000, including USD 35,000 deferred until the company receives capital investments resulting in USD 3,000,000 of proceeds. His base salary increases to USD 350,000 if aggregate capital investments reach USD 5,000,000 during his employment. He is eligible for an annual performance bonus of up to 50% of base salary, received 20,000 RSUs that vested at the merger closing, and options to purchase 800,000 shares under the 2026 Equity Incentive Plan, subject to vesting conditions.
Niki BioSolutions, Inc. (NIKI) has filed a Form S-3 shelf registration (as amended by Pre-Effective Amendment No. 1) to offer, from time to time, an aggregate of up to $75,000,000 of common stock, preferred stock, warrants, subscription rights, debt securities and units. This new S-3 replaces a prior Form F-3 shelf, as the company is no longer a foreign private issuer and no securities were sold under that earlier filing.
Niki BioSolutions is a clinical-stage life sciences company focused on genomic and biomarker testing through a CLIA-certified, CAP-accredited lab, with its common stock listed on Nasdaq under the symbol NIKI. As of August 25, 2026, public float was $20.4 million, and the company qualifies as a smaller reporting company, limiting primary offerings to no more than one-third of that float in any 12‑month period while the float remains below $75 million. The company has experienced recent net losses, and its and DiamiR Biosciences Corp.’s audited financial statements carry going concern explanatory paragraphs from their auditors.
Unless specified otherwise in a prospectus supplement, net proceeds from any future takedowns under this shelf will be used for general corporate purposes, including working capital and potentially repayment of outstanding debt. The filing also describes the capital structure, including common stock, non‑voting non‑convertible Series A preferred stock with a 70/30 liquidation allocation, existing warrants, and standard Delaware anti‑takeover and indemnification provisions.
Niki BioSolutions, Inc. (NIKI) filed an amended report to add audited financials for its acquired subsidiary DiamiR Biosciences Corp. and unaudited pro forma combined financial information following their July 20, 2026 merger and Aptorum’s domestication and name change to Niki.
For the years ended May 31, 2026 and 2025, DiamiR reported revenue of $190,355 and $631,729 and net losses of $659,936 and $743,235, respectively. As of May 31, 2026, DiamiR had total assets of $618,078, total liabilities of $2,211,981 and a stockholders’ deficit of $1,593,903, including $1,314,150 of related-party convertible notes payable and a $65,000 loan from Aptorum.
DiamiR’s auditors and management highlight a going concern uncertainty due to recurring losses, negative cash flows and the need for additional capital. Purchase price allocation records $8.24 million of patents, $6.78 million of in-process R&D, $1.58 million of tradename assets and $1.08 million of goodwill. Pro forma, the combined company shows net losses of $2.05 million for the six months ended June 30, 2026 and $3.60 million for 2025.
Niki BioSolutions, Inc. (NIKI) furnished unaudited consolidated financial statements for the six months ended June 30, 2026, in connection with its transition from foreign private issuer to domestic issuer status and to update its existing registration statements. The company reported a net loss of $1.31 million, no revenue, and operating cash outflow of $1.55 million. Cash declined to $1.83 million with negative working capital of $2.48 million and an accumulated deficit of $75.12 million, while long-term non-marketable investments, primarily in Alzheon, remained at $15.10 million and are pledged against a related-party convertible note.
Management concluded that recurring losses, limited liquidity and DiamiR’s financial profile raise substantial doubt about the group’s ability to continue as a going concern. On July 20, 2026, after the reporting date, Aptorum completed its domestication to Delaware, changed its name to Niki BioSolutions, closed the merger with DiamiR Biosciences Corp., and issued 1,979,216 Niki common shares to DiamiR stockholders and 814,375 common shares plus 179,693 Series A preferred shares to existing Aptorum shareholders. Warrant liabilities decreased from $306,000 to $142,000, generating a fair value gain, and the company disclosed an ongoing lawsuit in U.S. federal court that it is contesting.
Niki BioSolutions, Inc. reports the initial equity position of director Arner Douglas Wayne. As of 2026-07-20, he is shown as directly holding 1,062 shares of the company’s Common Stock. This filing establishes his baseline beneficial ownership stake as a board member.
Niki BioSolutions, Inc. director Justin Che Yuen Wu filed an initial statement of beneficial ownership. The filing reports 1,832 shares of Common Stock held with direct ownership as of 2026-07-20. The entry records holdings only, without any reported purchase or sale transaction.